<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649646</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-OS-404</org_study_id>
    <nct_id>NCT03649646</nct_id>
  </id_info>
  <brief_title>FimasaRtan-basEd BP Targets After Drug SwitcHing</brief_title>
  <acronym>FRESH</acronym>
  <official_title>A Multi-center, Open, Longitudinal, Observational Study to Assess the Treatment Trend and the Proportion of Target BP Attainment in Patients Whose Antihypertensive Regimens Are Changed to ARB-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent hypertension clinical practice guidelines published by American College of&#xD;
      Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg,&#xD;
      indicating the needs for more aggressive efforts in hypertension treatment. However, studies&#xD;
      in Koreans must be preceded before applying such new overseas guidelines; thus, this study&#xD;
      has been designed to establish clinical materials reflecting treatment setting in Korea. In&#xD;
      this study, patients with uncontrolled hypertension whose antihypertensive regimens are&#xD;
      changed to ARB-based therapy (ARB monotherapy or ARB-containing combination therapy) will be&#xD;
      followed to assess the treatment trend, treatment effect, and risk of cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed in patients with blood pressure (BP) uncontrolled by existing&#xD;
      antihypertensive drugs (including ARB) among hypertensive patients visiting outpatient clinic&#xD;
      of medical institutions in Korea. The study enrollment number will be assigned to the&#xD;
      subjects who provide a written consent to the use of personal information and meet the&#xD;
      inclusion/exclusion criteria. Follow-up will be conducted for 12 weeks in total and&#xD;
      prespecified study related data will be collected in the case report form.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Actual">October 29, 2020</completion_date>
  <primary_completion_date type="Actual">October 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Controlled Blood Pressure (&lt;140/90 mmHg)</measure>
    <time_frame>Week 12 after the treatment regimen change</time_frame>
    <description>Percentage of patients who attain the target blood pressure (BP) (&lt;140(SBP)/90(DBP) mmHg) at Week 12 after the treatment regimen change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Controlled BP According to 2018 KSH Guideline</measure>
    <time_frame>Week 12 after the treatment regimen change</time_frame>
    <description>Percentage of patients who attain the target BP specified in 2018 hypertension clinical practice guidelines* suggested by Korean Society of Hypertension at Week 12 after the treatment regimen change.&#xD;
*2018 hypertension clinical practice guidelines : Target BP &lt;140(SBP)/90(DBP) mmHg.&#xD;
For patients meeting any of the conditions listed below, each corresponding criterion will be applied.&#xD;
Patients with cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with diabetes : &lt;140/85 mmHg&#xD;
Patients with diabetes accompanying cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with chronic kidney disease accompanying albuminuria: &lt;130/80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Controlled BP According to 2017 ACC/AHA Guideline</measure>
    <time_frame>Week 12 after the treatment regimen change</time_frame>
    <description>Percentage of patients who attain the target BP(&lt;130(SBP)/80(DBP)mmHg) specified in 2017 clinical practice guidelines for hypertension suggested by American College of Cardiology(ACC)/American Heart Association(AHA) at Week 12 after the treatment regimen change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prcentage of Patients With Controlled BP According to Investigator's Target BP</measure>
    <time_frame>Week 12 after the treatment regimen change</time_frame>
    <description>Percentage of patients who attain the investigator's target BP* at Week 12 after the treatment regimen change.&#xD;
*Investigator's target BP: Target BP for each patient set by the investigator at baseline.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4542</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypertension uncontrolled by antihypertensive drugs* whose antihypertensive&#xD;
        regimens are changed to angiotensin receptor blocker (ARB) monotherapy or concomitant&#xD;
        antihypertensive drug therapy containing ARB.&#xD;
&#xD;
        *Including patients who previously received angiotensin receptor blocker (ARB); in this&#xD;
        case, changing to other therapy using an ARB with different ingredient is allowed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provided written consent to the use of personal information after receiving the&#xD;
             explanation of the objective, methodology, etc. of this clinical study&#xD;
&#xD;
          -  Male or female adults â‰¥ 19 years who are diagnosed with essential hypertension&#xD;
&#xD;
          -  Receiving outpatient treatment at the time of study enrollment&#xD;
&#xD;
          -  Patients with hypertension uncontrolled by existing antihypertensive drugs (including&#xD;
             ARB) whose antihypertensive regimens decided and scheduled to be changed to ARB&#xD;
             monotherapy or ARB-containing combination therapy (the result of the arm with a higher&#xD;
             mean BP [systolic BP preferred] when measured twice with at least a 2-minute interval&#xD;
             in both arms at the medical office on the study enrollment date, will become the&#xD;
             reference)&#xD;
&#xD;
               -  Definition of uncontrolled hypertension: Target BP (SBP &lt;140 mmHg and DBP &lt;90&#xD;
                  mmHg) not achieved even after the treatment using the existing antihypertensive&#xD;
                  drugs for 4 weeks or longer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were hospitalized or are scheduled to be hospitalized 4 weeks before or&#xD;
             after the study enrollment date&#xD;
&#xD;
          -  Patients with suspected or confirmed secondary hypertension&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients who received investigational product within 12 weeks or are scheduled to&#xD;
             participate in another clinical study while participating in this study&#xD;
&#xD;
          -  Patients who are determined inappropriate for participating in the study by&#xD;
             investigators for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Sook Hong</last_name>
    <role>Study Director</role>
    <affiliation>Boryung Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <results_first_submitted>November 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Fimasartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03649646/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients</title>
          <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4542"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4075"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="467"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients</title>
          <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4075"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.63" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/ãŽ¡</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.33" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Controlled Blood Pressure (&lt;140/90 mmHg)</title>
        <description>Percentage of patients who attain the target blood pressure (BP) (&lt;140(SBP)/90(DBP) mmHg) at Week 12 after the treatment regimen change</description>
        <time_frame>Week 12 after the treatment regimen change</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Controlled Blood Pressure (&lt;140/90 mmHg)</title>
          <description>Percentage of patients who attain the target blood pressure (BP) (&lt;140(SBP)/90(DBP) mmHg) at Week 12 after the treatment regimen change</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Controlled BP According to 2018 KSH Guideline</title>
        <description>Percentage of patients who attain the target BP specified in 2018 hypertension clinical practice guidelines* suggested by Korean Society of Hypertension at Week 12 after the treatment regimen change.&#xD;
*2018 hypertension clinical practice guidelines : Target BP &lt;140(SBP)/90(DBP) mmHg.&#xD;
For patients meeting any of the conditions listed below, each corresponding criterion will be applied.&#xD;
Patients with cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with diabetes : &lt;140/85 mmHg&#xD;
Patients with diabetes accompanying cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with chronic kidney disease accompanying albuminuria: &lt;130/80 mmHg</description>
        <time_frame>Week 12 after the treatment regimen change</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Controlled BP According to 2018 KSH Guideline</title>
          <description>Percentage of patients who attain the target BP specified in 2018 hypertension clinical practice guidelines* suggested by Korean Society of Hypertension at Week 12 after the treatment regimen change.&#xD;
*2018 hypertension clinical practice guidelines : Target BP &lt;140(SBP)/90(DBP) mmHg.&#xD;
For patients meeting any of the conditions listed below, each corresponding criterion will be applied.&#xD;
Patients with cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with diabetes : &lt;140/85 mmHg&#xD;
Patients with diabetes accompanying cardiovascular disease :&lt;130/80 mmHg&#xD;
Patients with chronic kidney disease accompanying albuminuria: &lt;130/80 mmHg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Controlled BP According to 2017 ACC/AHA Guideline</title>
        <description>Percentage of patients who attain the target BP(&lt;130(SBP)/80(DBP)mmHg) specified in 2017 clinical practice guidelines for hypertension suggested by American College of Cardiology(ACC)/American Heart Association(AHA) at Week 12 after the treatment regimen change</description>
        <time_frame>Week 12 after the treatment regimen change</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Controlled BP According to 2017 ACC/AHA Guideline</title>
          <description>Percentage of patients who attain the target BP(&lt;130(SBP)/80(DBP)mmHg) specified in 2017 clinical practice guidelines for hypertension suggested by American College of Cardiology(ACC)/American Heart Association(AHA) at Week 12 after the treatment regimen change</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prcentage of Patients With Controlled BP According to Investigator's Target BP</title>
        <description>Percentage of patients who attain the investigator's target BP* at Week 12 after the treatment regimen change.&#xD;
*Investigator's target BP: Target BP for each patient set by the investigator at baseline.</description>
        <time_frame>Week 12 after the treatment regimen change</time_frame>
        <population>Missing of investigator's target BP: 4 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
          </group>
        </group_list>
        <measure>
          <title>Prcentage of Patients With Controlled BP According to Investigator's Target BP</title>
          <description>Percentage of patients who attain the investigator's target BP* at Week 12 after the treatment regimen change.&#xD;
*Investigator's target BP: Target BP for each patient set by the investigator at baseline.</description>
          <population>Missing of investigator's target BP: 4 patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4071"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 12</time_frame>
      <desc>SAEs and antihypertensive drug related ADRs were collected during the study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients</title>
          <description>Patients with hypertension uncontrolled by antihypertensive drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="4386"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Myung Sook Hong</name_or_title>
      <organization>Boryung Pharm. CO., LTD</organization>
      <phone>82-2-708-8238</phone>
      <email>mshong@boryung.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

